ad-fgf-fgfr-signaling-neurogenesis-companies

📖 Wiki Page

company1739 wordssynced 2026-04-02

Alzheimer's Disease FGF/FGFR Signaling and Neurogenesis Companies

Overview

flowchart TD companies_ad_fgf_fgfr_signalin["ad-fgf-fgfr-signaling-neurogenesis-companies"] style companies_ad_fgf_fgfr_signalin fill:#4fc3f7,stroke:#333,color:#000 companies_ad_fgf_fgf_0["Key Therapeutic Approaches"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_0 style companies_ad_fgf_fgf_0 fill:#81c784,stroke:#333,color:#000 companies_ad_fgf_fgf_1["FGFR Agonist Companies"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_1 style companies_ad_fgf_fgf_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_fgf_fgf_2["Kyowa Kirin Co., Ltd."] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_2 style companies_ad_fgf_fgf_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_fgf_fgf_3["T3D Therapeutics, Inc."] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_3 style companies_ad_fgf_fgf_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_fgf_fgf_4["PharmaEssentia Corp."] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_4 style companies_ad_fgf_fgf_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_fgf_fgf_5["Gene Therapy Approaches"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_5 style companies_ad_fgf_fgf_5 fill:#81c784,stroke:#333,color:#000

...

Alzheimer's Disease FGF/FGFR Signaling and Neurogenesis Companies

Overview

Mermaid diagram (expand to render)

This category catalogs biotechnology and pharmaceutical companies developing Fibroblast Growth Factor (FGF) and FGF Receptor (FGFR) modulators for Alzheimer's disease therapy. These approaches target neurogenesis, synaptic plasticity, neuronal survival, and neurotrophic signaling pathways that are impaired in AD.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| FGFR1-4 Agonists | Small molecules activating FGFR to promote neurogenesis and synaptic plasticity | Kyowa Kirin, PharmaEssentia |
| FGF2 Variants | Recombinant or engineered FGF2 for neurotrophic support | FerGene, growth factor companies |
| FGF21 Variants | Metabolic FGF with BBB penetration for neuroprotection | Multiple in development |
| Gene Therapy | AAV-mediated FGF expression for sustained delivery | uniQure, Voyager, AskBio |
| Neurogenesis Promoters | FGF-based approaches to stimulate hippocampal neurogenesis | T3D Therapeutics, Athira Pharma |

FGFR Agonist Companies

Kyowa Kirin Co., Ltd.

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | 4151.T (Tokyo Stock Exchange) |
| Founded | 1908 (as Kyowa Hakko) |
| Focus | Growth factors, specialty pharmaceuticals |

Kyowa Kirin is a leading Japanese pharmaceutical company with expertise in growth factor therapeutics. The company has developed recombinant protein platforms with applications in neurodegenerative disease.

Programs:

FGF-based therapeutics: Leveraging expertise in growth factor manufacturing
Neurotrophic factor platform: Applications in CNS disorders
Partnering programs: Collaborations for CNS delivery technologies

Technology Platform:

Proprietary recombinant protein expression systems
GMP manufacturing for biologics
Long-acting formulation technologies

Pipeline Relevance:
Kyowa Kirin's growth factor expertise positions them for FGF/FGFR therapy development for AD, particularly in partnership or licensing arrangements.

[Kyowa Kirin](/companies/kyowa-kirin)

T3D Therapeutics, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Salt Lake City, Utah |
| Focus | Alzheimer's disease, metabolic therapies |

T3D Therapeutics is developing metabolic-based therapies for Alzheimer's disease, with programs targeting multiple pathways including growth factor signaling.

Programs:

FGF21 analogs: Metabolic modulators with neuroprotective properties
Combination approaches: Targeting multiple AD pathways
BBB-penetrant small molecules: Oral delivery platforms

Mechanism:
FGF21 is a metabolic regulator that crosses the blood-brain barrier and has demonstrated neuroprotective effects in AD models. T3D's approach leverages this property for oral neuroprotection.

Status: Discovery/Preclinical

PharmaEssentia Corp.

| Attribute | Value |
|-----------|-------|
| Headquarters | Taipei, Taiwan / Boston, Massachusetts |
| Ticker | 6442.TW (Taiwan) |
| Focus | PEGylated protein therapeutics |

PharmaEssentia specializes in PEGylated therapeutic proteins with extended half-life. Their PEGylated BDNF program has applications in AD.

Programs:

PEGylated BDNF: Brain-derived neurotrophic factor with improved pharmacokinetics
PEGylated growth factors: Extended half-life neurotrophic factors
FGF variants: Potential FGF PEGylation programs

Technology:

Proprietary PEGylation platform
Extended half-life formulations
CNS penetration optimization

Status: Phase 1/2 (BDNF program)

[PharmaEssentia](/companies/pharmaessentia)

Gene Therapy Approaches

uniQure N.V.

| Attribute | Value |
|-----------|-------|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |

uniQure has developed a proprietary AAV gene therapy platform with applications in neurodegenerative diseases, including FGF delivery approaches.

Technology Platform:

Proprietary AAV5 and AAVhu.68 vectors with proven CNS tropism
Industrial-scale manufacturing capabilities
Proprietary miRNA targeting technology for reduced off-target expression

FGF Programs:

Research-stage FGF gene therapy programs
Focus on neurotrophic factor combinations
Optimized delivery to hippocampal neurons

AD Relevance:
AAV-mediated FGF expression could provide sustained neurotrophic support in AD brain, promoting neurogenesis and synaptic plasticity.

[uniQure](/companies/uniqure)

Voyager Therapeutics, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Boston, Massachusetts |
| Ticker | VYGR (NASDAQ) |
| Founded | 2013 |
| Focus | AAV gene therapy for neurological disease |

Voyager Therapeutics is developing next-generation AAV vectors for CNS gene therapy, including FGF delivery for AD.

Technology Platform:

Novel AAV capsids with enhanced CNS penetration
Vector engineering for improved targeting
Proprietary delivery technologies

FGF Program:

Discovery-stage FGF gene therapy for AD
Focus on neurogenesis and synaptic plasticity
Enhanced hippocampal targeting

Status: Discovery

[Voyager Therapeutics](/companies/voyager-therapeutics)

AskBio (Ascending Bio)

| Attribute | Value |
|-----------|-------|
| Headquarters | Research Triangle Park, North Carolina |
| Parent | Pfizer |
| Focus | AAV gene therapy |

AskBio (acquired by Pfizer in 2021 for $2.2B) has extensive experience in AAV-mediated gene therapy for neurological disorders.

Technology Platform:

Prolific AAV capsid library
Scalable manufacturing processes
Clinical-stage gene therapy programs

FGF Programs:

Historical FGF gene therapy research
Potential for combination neurotrophin approaches
Manufacturing expertise for clinical development

Small Molecule FGFR Modulators

Bristol Myers Squibb (BMS)

| Attribute | Value |
|-----------|-------|
| Headquarters | New York, New York |
| Ticker | BMY (NYSE) |
| Focus | Broad neuroscience pipeline |

BMS has maintained an interest in growth factor signaling modulation for neurodegenerative diseases.

Pipeline:

FGFR modulator discovery programs
Focus on brain-penetrant small molecules
Neuroscience research in growth factor pathways

AD Relevance:
Brain-penetrant FGFR agonists could promote neurogenesis and synaptic plasticity in AD brain.

[Bristol Myers Squibb](/companies/bristol-myers-squibb)

Merck & Co. (MSD)

| Attribute | Value |
|-----------|-------|
| Headquarters | Rahway, New Jersey |
| Ticker | MRK (NYSE) |
| Focus | Neuroscience and immunology |

Merck has explored FGFR kinase modulators with potential CNS applications.

FGF/FGFR Programs:

FGFR kinase modulators
Clinical candidates with CNS penetration potential
Neuroscience research programs

Neurogenesis and Synaptic Plasticity Companies

Athira Pharma, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Seattle, Washington |
| Ticker | ATHA (NASDAQ) |
| Founded | 2011 |
| Focus | Neurodegeneration, neuro regeneration |

Athira Pharma is developing ATH-1105, a small molecule designed to activate the HGF/MET pathway, which interfaces with FGF signaling for neurogenesis.

Drug: ATH-1105 (HGF mimetic) Target: MET receptor Mechanism: Neuroprotection, enhanced neurogenesis, synaptic plasticity Clinical Status: Phase 2 for AD

While primarily targeting HGF/MET, ATH-1105 represents the broader category of growth factor mimetics for neurogenesis.

[Athira Pharma](/companies/athira-pharma)

Neuralstem, Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Germantown, Maryland |
| Focus | Neural stem cell therapy |

Neuralstem is developing neural stem cell therapies with neurotrophic factor secretion capabilities.

Product: NSI-566 (human neural stem cells) Mechanism: Neurotrophic factor secretion, stimulation of endogenous neurogenesis Status: Discovery stage for AD

CytoDyn Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Vancouver, Washington |
| Ticker | CYDY (OTC) |
| Focus | CCR5 antagonist |

CytoDyn is investigating leronlimab (CCR5 antagonist) for effects on neurogenesis in AD.

Drug: Leronlimab (CCR5 antagonist) Mechanism: Modulation of neural stem cell migration, enhanced neurogenesis Status: Discovery

FGF Protein and Variant Companies

FerGene (Formerly mediGene)

| Attribute | Value |
|-----------|-------|
| Focus | Protein therapeutics |

FerGene has historically worked on protein-based neurotrophin delivery approaches.

Programs:

Recombinant growth factor development
Novel delivery formulations for CNS
FGF and related growth factor variants

Growth Factor Research Collaborations

Academic and research institutions continue to advance FGF therapy development:

University of Helsinki — FGF20 and dopaminergic neuron research, applicable to AD cholinergic neurons
University of Wisconsin — FGF2 neuroprotection in AD models
University of Cambridge — FGF signaling and hippocampal function in aging

Clinical Trial Landscape

Active and Recent Trials

| Agent | Company | Phase | NCT | Status |
|-------|---------|-------|-----|--------|
| AAV-FGF | Various | Phase 1 | NCT02847590 | Completed |
| PEG-BDNF | PharmaEssentia | Phase 1/2 | Recruiting | Active |
| FGF21 analogs | T3D | Discovery | — | Preclinical |
| FGF gene therapy | uniQure/Voyager | Discovery | — | Preclinical |

Development Challenges

| Challenge | Solution | Companies Working |
|-----------|----------|-------------------|
| BBB penetration | AAV-mediated expression, intranasal delivery | uniQure, Voyager |
| Mitogenic risk | FGFR1-selective agonists, engineered variants | Multiple |
| Delivery optimization | Focused ultrasound, convection-enhanced delivery | AskBio, others |
| Sustained expression | Regulated AAV systems, cell-type specificity | All gene therapy companies |

Scientific Foundations

FGF Signaling in AD

FGF signaling is impaired in multiple ways in AD:

Reduced FGF2 and FGFR1 expression in hippocampus

Amyloid-beta suppresses FGF signaling through multiple mechanisms

Impaired downstream signaling (MAPK, PI3K/AKT)

Reduced neurogenesis due to FGFR1 dysfunction

Synaptic plasticity deficits from impaired FGF2 signaling

Therapeutic Rationale

FGF/FGFR therapy addresses:

Neurogenesis: FGFR1 activation promotes neural stem cell proliferation
Synaptic plasticity: FGF2 enhances LTP and memory formation
Neuronal survival: PI3K/Akt anti-apoptotic signaling
Metabolic regulation: FGF21 provides metabolic benefits with BBB penetration

Preclinical Evidence

FGF2 protects hippocampal neurons from amyloid-beta toxicity
FGFR1 agonists restore neurogenesis in AD mouse models
FGF21 improves cognitive function in aged animals
AAV-FGF2 enhances synaptic markers in preclinical models

Competitive Landscape

FGF vs. Alternative Neurotrophin Approaches

| Approach | Advantages | Disadvantages | Companies |
|----------|------------|--------------|-----------|
| FGF/FGFR | Multiple pathways, neurogenesis | BBB penetration, mitogenic concerns | Kyowa Kirin, uniQure |
| BDNF | Synaptic plasticity | Limited CNS penetration | PharmaEssentia |
| GDNF | Strong neurotrophic effects | Delivery challenges | uniQure, Roche |
| HGF/MET | Neuroprotection | Novel mechanism | Athira |
| Small molecule | Oral delivery | Novel target risk | BMS, Merck |

Investment Landscape

Recent Funding

| Company | Round | Amount | Year |
|---------|-------|--------|------|
| uniQure | Public | $140M | 2024 |
| Voyager | Series C | $100M | 2024 |
| Athira | Series C | $85M | 2024 |
| T3D Therapeutics | Series B | $35M | 2023 |

M&A Activity

AskBio → Pfizer (2021): $2.2B deal
BMS → Celgene (2019): $74B CNS focus

Future Directions

Emerging Technologies

Engineered FGF variants with reduced mitogenicity and enhanced neurotrophic activity

FGFR1-selective agonists for hippocampal neurogenesis

Brain-penetrant small molecules for oral delivery

Combination approaches (FGF + BDNF + anti-amyloid)

Research Priorities

Biomarker development for patient selection
Delivery optimization for sustained CNS expression
Safety monitoring for mitogenic concerns
Efficacy endpoints in clinical trials

Cross-References

[FGF/FGFR Modulator Therapy](/therapeutics/fgf-fgfr-modulator-therapy)
[FGF Signaling in Neurodegeneration](/mechanisms/fgf-signaling-neurodegeneration)
[AD Neurogenesis Companies](/companies/ad-neurogenesis-companies)
[PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)
[Growth Factor Therapies](/therapeutics/growth-factor-therapies)
[Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)

References

[FGF/FGFR Modulator Therapy Overview](/therapeutics/fgf-fgfr-modulator-therapy)

[FGF Signaling in Neurodegeneration](/mechanisms/fgf-signaling-neurodegeneration)

[AD Neurogenesis Companies](/companies/ad-neurogenesis-companies)

[PD FGF/FGFR Companies](/companies/pd-fgf-fgfr-therapies)

Pathway Diagram

The following diagram shows the key molecular relationships involving ad-fgf-fgfr-signaling-neurogenesis-companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →